| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | T-cell surface glycoprotein CD4, T-cell surface antigen T4/Leu-3, CD4, CD4 |
| Entrez GeneID | 920 |
| WB Predicted band size | 51.1kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This CD4 Monoclonal antibody is generated from mouses immunized with a KLH conjugated synthetic peptide selected from human CD4. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3条关于CD4抗体的代表性文献概览：
---
1. **文献名称**: *CD4 is the receptor for human immunodeficiency virus (HIV)*
**作者**: Klatzmann D, et al.
**摘要**: 该研究首次证实CD4分子是HIV病毒进入T细胞的主要受体，揭示了HIV感染靶细胞的关键机制，为后续抗病毒药物和抗体疗法开发奠定了基础。
---
2. **文献名称**: *Therapeutic targeting of CD4 in autoimmune diseases using blocking antibodies*
**作者**: Choy EH, et al.
**摘要**: 探讨了抗CD4单克隆抗体通过抑制CD4+T细胞活性，减轻类风湿性关节炎等自身免疫疾病症状的潜力，并通过临床试验验证其安全性和部分疗效。
---
3. **文献名称**: *Structural basis for CD4 downregulation by HIV-1 Nef*
**作者**: Lee CH, et al.
**摘要**: 通过解析CD4与HIV蛋白Nef的复合物结构，揭示了HIV逃避免疫系统的分子机制，为设计靶向CD4-HIV相互作用的新型抗体或抑制剂提供结构生物学依据。
---
如需更多文献或特定研究方向，可进一步补充说明。
CD4 antibodies are essential tools in immunology, targeting the CD4 glycoprotein expressed primarily on helper T cells, regulatory T cells, monocytes, macrophages, and dendritic cells. The CD4 molecule serves as a co-receptor for T-cell receptor (TCR) signaling by binding to MHC class II molecules on antigen-presenting cells, thereby stabilizing TCR-peptide-MHC interactions and enhancing T-cell activation. Additionally, CD4 acts as a primary receptor for HIV-1 entry via its interaction with the viral envelope glycoprotein gp120.
CD4 antibodies are classified into agonist or antagonist types based on their functional effects. Agonist antibodies (e.g., anti-CD3/CD28) mimic antigen presentation, inducing T-cell activation and proliferation, which is useful in immunotherapy research. Antagonist antibodies block CD4-MHC II interactions, suppressing T-cell responses, making them valuable in treating autoimmune diseases or preventing transplant rejection. Clinically, CD4 antibodies like OKT4 or Leu-3 have been used to study T-cell subsets, monitor HIV progression (via CD4+ T-cell counts), and develop therapeutic strategies such as checkpoint inhibitors in cancer immunotherapy.
In HIV research, CD4 antibodies help map viral entry mechanisms and evaluate entry inhibitors. However, therapeutic use faces challenges, including transient immunosuppression or cytokine release syndromes. Despite this, CD4 antibodies remain pivotal in understanding adaptive immunity and developing targeted therapies.
×
